Your browser is no longer supported. Please, upgrade your browser.
SESN Sesen Bio, Inc. daily Stock Chart
Sesen Bio, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own6.56% Shs Outstand73.10M Perf Week2.02%
Market Cap61.41M Forward P/E- EPS next Y-0.34 Insider Trans- Shs Float72.38M Perf Month11.75%
Income-33.50M PEG- EPS next Q-0.08 Inst Own54.40% Short Float7.36% Perf Quarter-50.29%
Sales0.00M P/S- EPS this Y51.40% Inst Trans9.49% Short Ratio3.31 Perf Half Y-56.24%
Book/sh0.65 P/B1.29 EPS next Y37.00% ROA-33.60% Target Price3.50 Perf Year-6.66%
Cash/sh0.79 P/C1.06 EPS next 5Y- ROE-85.70% 52W Range0.66 - 3.50 Perf YTD-40.84%
Dividend- P/FCF- EPS past 5Y39.70% ROI-162.50% 52W High-76.00% Beta1.97
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low27.11% ATR0.06
Employees17 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)49.24 Volatility5.02% 7.28%
OptionableYes Debt/Eq0.00 EPS Q/Q50.70% Profit Margin- Rel Volume0.97 Prev Close0.79
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 BMO Payout- Avg Volume1.61M Price0.84
Recom1.80 SMA2010.61% SMA50-17.27% SMA200-52.36% Volume1,555,797 Change5.95%
Jan-22-19 09:30AM  Health Stocks Benefitting the Most from Rally ACCESSWIRE
Jan-18-19 11:36AM  Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment Simply Wall St.
Jan-03-19 06:30AM  Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer Business Wire -36.74%
Dec-27-18 12:45PM  4 Healthcare Stocks That Could Test December Highs ACCESSWIRE +6.50%
06:30AM  Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer Business Wire
Dec-03-18 06:30AM  Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer Business Wire
Nov-08-18 09:50AM  3 Health Care Stocks Seeing Heightened Activity After Midterms ACCESSWIRE +20.78%
06:30AM  Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts Business Wire
Oct-15-18 08:40AM  Implied Volatility Surging for Sesen Bio (SESN) Stock Options Zacks
Sep-27-18 11:53AM  Do Institutions Own Shares In Sesen Bio Inc (NASDAQ:SESN)? Simply Wall St. +8.08%
Sep-20-18 08:27AM  Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018 Business Wire
Sep-05-18 11:45AM  Here's Why Momentum Investors Will Love Sesen Bio (SESN) Zacks
04:46AM  Sesen Bio (SESN) Continue to Surge Higher? Zacks
Aug-31-18 12:45PM  3 Cancer Treatment Stocks that Moved Higher in August ACCESSWIRE +9.27%
Aug-14-18 06:30AM  Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates Business Wire
Aug-09-18 06:30AM  Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer Business Wire +12.34%
Aug-07-18 04:01PM  Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019 Business Wire
Aug-02-18 06:30AM  Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference Business Wire
Jul-27-18 07:55AM  Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks ACCESSWIRE -5.06%
Jun-20-18 07:50AM  Stock Performance Review on Sesen Bio and Three Other Biotech ACCESSWIRE
Jun-05-18 09:04AM  Sesen Bio (SESN) Sees Hammer Chart Pattern: Time to Buy? Zacks +6.06%
Jun-04-18 04:01PM  Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock Business Wire
May-30-18 09:22PM  Sesen Bio Announces Pricing of Public Offering of Common Stock Business Wire +9.09%
04:00PM  Sesen Bio Announces Proposed Public Offering of Common Stock Business Wire
May-29-18 06:30AM  Sesen Bio to Present at the Jefferies 2018 Global Healthcare Conference Business Wire -5.17%
May-21-18 02:15PM  Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients Business Wire -23.00%
11:39AM  NasdaqGM Healthcare Industry: A Dive Into Sesen Bio Inc (NASDAQ:SESN) Simply Wall St.
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.